Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients
- 3 June 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (21), 2664-2669
- https://doi.org/10.1161/01.cir.0000074043.46437.44
Abstract
Background— Considerable evidence implicates the proinflammatory cytokine CD40 ligand (CD40L) in atherosclerosis and accumulating data link type 1 and 2 diabetes, conditions associated with accelerated atherosclerosis, to inflammation. This study therefore evaluated the hypothesis that diabetic patients have elevated plasma levels of soluble CD40L (sCD40L) and that treatment with the insulin-sensitizing thiazolidinediones lowers this index of inflammation. Methods and Results— Subjects with type 1 (n=49) or type 2 diabetes (n=48) had higher ( P P P 3 years) with or without macrovascular complications (−34% and −29%, respectively) as well as in type 2 diabetic patients with more recent (P Conclusions— This study provides new evidence that individuals with type 1 or 2 diabetes have a proinflammatory state as indicated by elevated levels of plasma sCD40L. Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease.This publication has 30 references indexed in Scilit:
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular CellsCirculation, 2002
- Diabetic macrovascular disease: the glucose paradox?Circulation, 2002
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJCI Insight, 2000
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionThe New England Journal of Medicine, 1998
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- Diabetes Nutrition and Complications Trial (DNCT): Food Intake and Targets of Diabetes Treatment in a Sample of Spanish People With DiabetesDiabetes Care, 1997
- Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular diseaseCoronary Artery Disease, 1996
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995